InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,537.02
(
0.51%
)
US TECH 100
19,641.60
(
0.83%
)
Dow Jones
39,308.00
(
-0.06%
)
Brent Oil
86.62
(
-0.34%
)
Bitcoin
58,813.07
(
-2.24%
)
Post# of 252478
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

poorgradstudent

Send PM Follow Ignore
Followers 73
Posts 3426
Boards Moderated 1
Alias Born 04/28/2004

poorgradstudent

Re: jq1234 post# 166766

Friday, 09/20/2013 2:34:57 PM

Friday, September 20, 2013 2:34:57 PM

Post# of 252478
Gotcha...

Lots of people are pointing to dosing and the AEs, but that's obviously irrelevant if the exon skipping is being promoted. IF these patients in the drisa trial had exon skipping and dystrophin production, then that's bad news for SRPT.

I'll be interested to see dystrophin data from this trial. The dystrophin data released by SRPT was spotty and unimpressive, so a more comprehensive report from this drisa trial will be nice to see.
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up